Arana begins Phase II
Thursday, 11 December, 2008
Arana Therapeutics has begun its Phase II trial of its domain antibody ART621 for rheumatoid arthritis.
The trial, which will recruit 200 patients, will held in eight countries, including Australia, the US and India.
It will test the efficacy of ART621 in rheumatoid arthritis and will compare three doses of ART621 with a placebo in patients also taking methotrexate, a common anti-metabolite that inhibits the metabolism of folic acid.
Results are due in mid-2010.
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
